I-Pembrolizumab, USFDA
I-Enfortumab vedotin-ejfv ene-pembrolizumab igunyazwe yi-USFDA nge-carcinoma ye-urothelial ethuthukisiwe endaweni noma e-metastatic.
Feb 2024: Ukuphathwa Kwezokudla Nezidakamizwa kusheshise inqubo yokugunyazwa kwezidakamizwa ezimbili, i-enfortumab vedotin-ejfv (Padcev, Astellas Pharma) kanye ne-pembrolizumab (Keytruda, Merck). Lezi zidakamizwa zenzelwe ukwelapha abantu endaweni ..
I-BMS, I-Bristol Myers squibb, immunotherapy, I-melanoma ye-metastatic, nivolumab futhi relatlimab, nivolumab futhi relatlimab-rmbw, I-Opdualag, USFDA
Inhlanganisela yokuqala ye-LAG-3-Blocking antibody, i-Opdualag™ (i-nivolumab ne-relatlimab-rmbw), igunyazwe yi-FDA ezigulini ezinemelanoma engahlanjululwayo noma ye-metastatic.
Ephreli 2022: I-US Food and Drug Administration (i-FDA) igunyaze i-Opdualag (nivolumab ne-relatlimab-rmbw), inhlanganisela yomthamo ongaguquki wezinga lokuqala le-nivolumab kanye ne-relatlimab elawulwa njengokufakwa emthanjeni okukodwa, i-f.
I-BMS, Breyanzi, Ukwelashwa kwe-CAR - T Cell, ISIMOTO SEMOTO, Ukwelashwa kwenqola, USFDA
IBreyanzi - Ukwelashwa okusha kwe-CAR T-Cell kusuka ku-BMS
Julayi 2021: I-Breyanzi (Lisocabtagene maraleucel; liso-cel), i-CD19-directed chimeric antigen receptor (CAR) T cell treatment eyakhiwe nguBristol Myers Squibb (BMS), ivunywe yi-US Food and Drug Administration (US.).
KEYTRUDA, Merck, I-NCT02362594, I-Pembrolizumab, KHUMBULA, USFDA
I-Pembrolizumab yamukelwa yi-FDA ekwelashweni nge-adjuvant kwe-melanoma
NgoFebhuwari 15, 2019, i-pembrolizumab (KEYTRUDA, Merck) yagunyazwa yiFood and Drug Administration yokwelapha i-adjuvant yeziguli ezinemelanoma ngokubandakanyeka kwe(ama)lymph node ngemuva kokuhlinzwa ngokuphelele. Imvume ..
I-Ablynx, ADAMUTS13, I-CABLIVI, i-caplacizumab-yhdp, FDA, ukwelashwa kokuzivikela komzimba, USFDA
ICaplacizumab-yhdp ivunyelwe yi-FDA
NgoFebhuwari 6, 2019, ngokuhlangana nokushintshaniswa kwe-plasma kanye nokwelashwa kwe-immunosuppressive, i-Food and Drug Administration igunyaze i-caplacizumab-yhdp (CABLIVI, Ablynx NV) yeziguli ezindala ezine-thrombotic cystopeni.
I-CABOMETYX, I-Cabozantinib, Exelixis, FDA, HCC, i-hepatocellular carcinoma, Sorafenib, USFDA
ICabozantinib ivunyiwe yi-FDA nge-hepatocellular carcinoma
NgoJanuwari 14, 2019, i-cabozantinib (CABOMETYX, Exelixis, Inc.) yagunyazwa yi-Food and Drug Administration yeziguli ezine-hepatocellular carcinoma (HCC) ezike zelashwa nge-sorafenib ngaphambilini. I-appr..
I-Acalabrutunib, I-Avelumab, Ukwelashwa kwenqola, Dabrafanib, UKymriah, Izidakamizwa zakamuva, I-Midostaurin, I-Niraparib, I-Pembrolizumab, UTecartus, Unyusibhabha, I-Trametinib, USFDA
Izidakamizwa zakamuva ekwelapheni umdlavuza
Julayi 2021: Hlola izidakamizwa zakamuva ekwelapheni umdlavuza. Minyaka yonke, ngemva kokuhlola izivivinyo nezinye izici ezibalulekile, i-USFDA ivuma izidakamizwa, futhi ngaleyo ndlela iziguli ezinomdlavuza manje zingakholwa ukuthi ikhambi seliseduze kakhulu. ..